---
figid: PMC6880611__fendo-10-00788-g0001
figlink: /pmc/articles/PMC6880611/figure/F1/
number: Figure 1
caption: 'The role of insulin signaling and insulin resistance in MetS and skin diseases.
  Insulin binds to insulin receptor (IR) and phosphorylates insulin receptor substrates
  (IRS-1, IRS-2) and Shc, which activates the two main insulin signaling pathways:
  the phosphatidylinositol-3-kinase (PI3K)/Akt pathway and the mitogen-activated protein
  kinases (MAPK)/Ras pathway. Under insulin resistance and compensatory hyperinsulinemia
  condition, insulin not only binds to IR, but also binds to IGF-receptors and stimulates
  the proliferation of keratinocytes and fibroblasts. Moreover, insulin resistance
  and compensatory hyperinsulinemia could decrease the expression of insulin-like
  growth factor binding proteins (IGFBPs), thus increasing biological active IGF-1
  and resulting in the development of hyperkeratosis and papillomatosis, which are
  demonstrated as the possible pathogenesis of acanthosis nigricans. As for acne vulgaris
  and hidradenitis suppurativa, western diet and puberty increase PI3K/Akt signaling
  and activate mTORC1. mTOR causes the serine/threonine phosphorylation of IRS by
  activating S6K and reduces its ability to be phosphorylated on tyrosine residues,
  which results in invalid insulin signaling and insulin resistance. mTORC1 also promotes
  lipid synthesis via activating the transcription factor sterol regulatory element
  binding protein 1 (SREBP-1) and inducing the expression of acetyl CoA carboxylase
  (ACC), which is the rate-limiting enzyme of fatty acid synthesis. In psoriasis,
  overactivation of PI3K and Akt phosphorylates FOXO and leads to its nuclear export,
  thus promoting cell proliferation by suppressing its function of activating cell
  cycle inhibitors (p27KIP1 and p21) and repressing cell cycle activators (cyclin
  D1/D2), which contributes to proliferation of keratinocytes. Moreover, in psoriatic
  condition, growth factors and relevant cytokines (IL-17A, TNF-α, and IL-1β) in psoriasis
  activate mTOR and then promote keratinocyte hyperproliferation and inhibiting differentiation.
  In the MAPK/Ras pathway, ERK1/2 could activate upstream MEK, reduce Akt phosphorylation,
  and contribute to insulin resistance. Furthermore, p-ERK1/2 have been identified
  to be increased in psoriatic skin, which results in the abnormal and proliferation
  and differentiation of keratinocytes.'
pmcid: PMC6880611
papertitle: Metabolic Syndrome and Skin Diseases.
reftext: Yu Hu, et al. Front Endocrinol (Lausanne). 2019;10:788.
pmc_ranked_result_index: '15051'
pathway_score: 0.8638478
filename: fendo-10-00788-g0001.jpg
figtitle: Insulin signaling and insulin resistance in MetS and skin diseases
year: '2019'
organisms: Homo sapiens
ndex: e180aa9d-df1e-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6880611__fendo-10-00788-g0001.html
  '@type': Dataset
  description: 'The role of insulin signaling and insulin resistance in MetS and skin
    diseases. Insulin binds to insulin receptor (IR) and phosphorylates insulin receptor
    substrates (IRS-1, IRS-2) and Shc, which activates the two main insulin signaling
    pathways: the phosphatidylinositol-3-kinase (PI3K)/Akt pathway and the mitogen-activated
    protein kinases (MAPK)/Ras pathway. Under insulin resistance and compensatory
    hyperinsulinemia condition, insulin not only binds to IR, but also binds to IGF-receptors
    and stimulates the proliferation of keratinocytes and fibroblasts. Moreover, insulin
    resistance and compensatory hyperinsulinemia could decrease the expression of
    insulin-like growth factor binding proteins (IGFBPs), thus increasing biological
    active IGF-1 and resulting in the development of hyperkeratosis and papillomatosis,
    which are demonstrated as the possible pathogenesis of acanthosis nigricans. As
    for acne vulgaris and hidradenitis suppurativa, western diet and puberty increase
    PI3K/Akt signaling and activate mTORC1. mTOR causes the serine/threonine phosphorylation
    of IRS by activating S6K and reduces its ability to be phosphorylated on tyrosine
    residues, which results in invalid insulin signaling and insulin resistance. mTORC1
    also promotes lipid synthesis via activating the transcription factor sterol regulatory
    element binding protein 1 (SREBP-1) and inducing the expression of acetyl CoA
    carboxylase (ACC), which is the rate-limiting enzyme of fatty acid synthesis.
    In psoriasis, overactivation of PI3K and Akt phosphorylates FOXO and leads to
    its nuclear export, thus promoting cell proliferation by suppressing its function
    of activating cell cycle inhibitors (p27KIP1 and p21) and repressing cell cycle
    activators (cyclin D1/D2), which contributes to proliferation of keratinocytes.
    Moreover, in psoriatic condition, growth factors and relevant cytokines (IL-17A,
    TNF-α, and IL-1β) in psoriasis activate mTOR and then promote keratinocyte hyperproliferation
    and inhibiting differentiation. In the MAPK/Ras pathway, ERK1/2 could activate
    upstream MEK, reduce Akt phosphorylation, and contribute to insulin resistance.
    Furthermore, p-ERK1/2 have been identified to be increased in psoriatic skin,
    which results in the abnormal and proliferation and differentiation of keratinocytes.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - AKT3
  - AKT1
  - AKT2
  - ELK1
  - MAPK3
  - MAPK1
  - FOXO6
  - FOXO1
  - FOXO3
  - FOXO4
  - GRB2
  - GSK3A
  - GSK3B
  - IGFBP1
  - IGFBP2
  - IGFBP3
  - IGFBP4
  - IGFBP5
  - IGFBP6
  - IGFBP7
  - IGF1R
  - IL17A
  - IL18
  - IRS4
  - IRS1
  - IRS2
  - MAP2K1
  - MAP2K2
  - PDK1
  - PIK3CA
  - PIK3R6
  - PIK3R5
  - PIK3R4
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - ARAF
  - RAF1
  - BRAF
  - HRAS
  - KRAS
  - NRAS
  - XRN1
  - SHC3
  - SHC2
  - SHC4
  - SHC1
  - SOS1
  - SOS2
  - TRIP10
  - TNF
  - TSC2
  - tinocylino
  - Hyperinsulinemia
  - tinocylino
genes:
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: Elk-1
  symbol: ELK1
  source: hgnc_symbol
  hgnc_symbol: ELK1
  entrez: '2002'
- word: ERK1/2
  symbol: ERK1
  source: hgnc_alias_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: ERK1/2
  symbol: ERK2
  source: hgnc_alias_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: FOXO
  symbol: FOXO
  source: bioentities_symbol
  hgnc_symbol: FOXO6
  entrez: '100132074'
- word: FOXO
  symbol: FOXO
  source: bioentities_symbol
  hgnc_symbol: FOXO1
  entrez: '2308'
- word: FOXO
  symbol: FOXO
  source: bioentities_symbol
  hgnc_symbol: FOXO3
  entrez: '2309'
- word: FOXO
  symbol: FOXO
  source: bioentities_symbol
  hgnc_symbol: FOXO4
  entrez: '4303'
- word: Grb2
  symbol: GRB2
  source: hgnc_symbol
  hgnc_symbol: GRB2
  entrez: '2885'
- word: GSK3
  symbol: GSK3
  source: bioentities_symbol
  hgnc_symbol: GSK3A
  entrez: '2931'
- word: GSK3
  symbol: GSK3
  source: bioentities_symbol
  hgnc_symbol: GSK3B
  entrez: '2932'
- word: IGFBP
  symbol: IGFBP
  source: bioentities_symbol
  hgnc_symbol: IGFBP1
  entrez: '3484'
- word: IGFBP
  symbol: IGFBP
  source: bioentities_symbol
  hgnc_symbol: IGFBP2
  entrez: '3485'
- word: IGFBP
  symbol: IGFBP
  source: bioentities_symbol
  hgnc_symbol: IGFBP3
  entrez: '3486'
- word: IGFBP
  symbol: IGFBP
  source: bioentities_symbol
  hgnc_symbol: IGFBP4
  entrez: '3487'
- word: IGFBP
  symbol: IGFBP
  source: bioentities_symbol
  hgnc_symbol: IGFBP5
  entrez: '3488'
- word: IGFBP
  symbol: IGFBP
  source: bioentities_symbol
  hgnc_symbol: IGFBP6
  entrez: '3489'
- word: IGFBP
  symbol: IGFBP
  source: bioentities_symbol
  hgnc_symbol: IGFBP7
  entrez: '3490'
- word: IGFR
  symbol: IGFR
  source: hgnc_alias_symbol
  hgnc_symbol: IGF1R
  entrez: '3480'
- word: IL-17A
  symbol: IL-17A
  source: hgnc_alias_symbol
  hgnc_symbol: IL17A
  entrez: '3605'
- word: IL-18
  symbol: IL-18
  source: hgnc_alias_symbol
  hgnc_symbol: IL18
  entrez: '3606'
- word: IRS
  symbol: IRS
  source: bioentities_symbol
  hgnc_symbol: IRS4
  entrez: '8471'
- word: IRS
  symbol: IRS
  source: bioentities_symbol
  hgnc_symbol: IRS1
  entrez: '3667'
- word: IRS
  symbol: IRS
  source: bioentities_symbol
  hgnc_symbol: IRS2
  entrez: '8660'
- word: MEK1/2
  symbol: MEK1
  source: hgnc_alias_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: MEK1/2
  symbol: MEK2
  source: hgnc_alias_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: PDK1
  symbol: PDK1
  source: hgnc_symbol
  hgnc_symbol: PDK1
  entrez: '5163'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: Sep-1
  symbol: SEP1
  source: hgnc_alias_symbol
  hgnc_symbol: XRN1
  entrez: '54464'
- word: Shc
  symbol: SHC
  source: bioentities_symbol
  hgnc_symbol: SHC3
  entrez: '53358'
- word: Shc
  symbol: SHC
  source: bioentities_symbol
  hgnc_symbol: SHC2
  entrez: '25759'
- word: Shc
  symbol: SHC
  source: bioentities_symbol
  hgnc_symbol: SHC4
  entrez: '399694'
- word: Shc
  symbol: SHC
  source: bioentities_symbol
  hgnc_symbol: SHC1
  entrez: '6464'
- word: SoS
  symbol: SOS
  source: bioentities_symbol
  hgnc_symbol: SOS1
  entrez: '6654'
- word: SoS
  symbol: SOS
  source: bioentities_symbol
  hgnc_symbol: SOS2
  entrez: '6655'
- word: STP
  symbol: STP
  source: hgnc_alias_symbol
  hgnc_symbol: TRIP10
  entrez: '9322'
- word: TNF-a
  symbol: TNF-alpha
  source: hgnc_alias_symbol
  hgnc_symbol: TNF
  entrez: '7124'
- word: TSC2
  symbol: TSC2
  source: hgnc_symbol
  hgnc_symbol: TSC2
  entrez: '7249'
chemicals:
- word: tinocylino
  source: ''
  identifier: ''
diseases:
- word: Hyperinsulinemia
  source: MESH
  identifier: D006946
- word: tinocylino
  source: ''
  identifier: ''
---
